TCGX is a biotechnology-focused investment firm. On October 7, 2026, TCGX announced the closing of TCGX Asia Life Sciences Fund I, an oversubscribed $600 million vehicle backed by international institutional investors to invest in innovative biotechnology companies based in Asia, operating in synergy with TCGX's flagship funds focused on the United States and Europe. In connection with the launch, TCGX is expanding operations in Asia with offices in Shanghai and Hong Kong.

Firm Profile

Notable Partners

Investment Focus

VCLife SciencesAsiaDaily Discovery

Investor data reflects publicly disclosed AUM, fund sizes, and portfolio holdings as of recent date. Refreshed periodically.